Literature DB >> 7833143

Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells.

M C Pagliacci1, M Smacchia, G Migliorati, F Grignani, C Riccardi, I Nicoletti.   

Abstract

Genistein, a natural isoflavonoid phyto-oestrogen, inhibits the tyrosine kinase activity of growth factor receptors and oncogene products, as well as the in vitro growth of some tumour cell lines. The low incidence of breast cancer in countries with a flavonoid-rich soy-based diet and the protection afforded by soy-derived products against experimental mammary tumours in rats suggest that genistein and other isoflavonoid compounds may exert an anti-tumour activity. We analysed the effects of genistein on cell number and cell cycle progression (flow cytometric analysis of propidium iodide-stained nuclei) of human breast cancer cells (MCF-7) in vitro. Genistein produced a significant, dose-dependent inhibition of MCF-7 cell growth with an ID50 of approximately 40 microM after 72 h of incubation. Cell cycle analysis showed a reversible G2/M arrest in cell cycle progression at 10 microM genistein concentrations, whilst a marked fall in S-phase cell percentage associated with a persistent arrest in G2/M phase was observed in cultures treated with genistein doses equal to or greater than 50 microM. These effects were significant at 24 h of incubation; flow cytometric analysis at later times (48 and 72 h) revealed a population of cells with decreased DNA content and nuclear fragmentation characteristic of apoptosis. Thus, the growth inhibitory activity of genistein in MCF-7 cells results from the sum of cytostatic and apoptotic effects. Since the mitogenic action of insulin and insulin-like growth factor (IGF)-I in MCF-7 cells is a tyrosine kinase-dependent phenomenon, we analysed the genistein impact on S-phase entry produced by insulin in cultures partially synchronised in G0/G1 phase by serum deprivation. Insulin addition after a 36-h culture period in serum-free medium produced a strong increase in the percentage of S-phase cells (from 18.4 +/- 2.3 to 46.2 +/- 4.1 after 24 h) which was almost completely blocked by 100 microM genistein (20.1 +/- 3.1). Immunofluorescence analysis with a fluoresceine isothiocyanate (FITC)-conjugated anti-phosphotyrosine antibody revealed a strong increase in MCF-7 cell staining after insulin stimulation, but not when genistein was added with insulin. In conclusion, the dietary phyto-oestrogen genistein inhibits in vitro growth of MCF-7 human breast cancer cells through blocks in the "critical checkpoints" of cell cycle control and induction of apoptosis. These effects are likely to depend on impairment in the signal transduction pathway from tyrosine kinase receptor(s).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7833143     DOI: 10.1016/0959-8049(94)00262-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  37 in total

1.  Phytoestrogens have agonistic and combinatorial effects on estrogen-responsive gene expression in MCF-7 human breast cancer cells.

Authors:  S T Willard; L S Frawley
Journal:  Endocrine       Date:  1998-04       Impact factor: 3.633

2.  Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice.

Authors:  Mengyuan Du; Xujuan Yang; James A Hartman; Paul S Cooke; Daniel R Doerge; Young H Ju; William G Helferich
Journal:  Carcinogenesis       Date:  2012-01-20       Impact factor: 4.944

3.  Tyrosine kinase-dependent release of an adenovirus preterminal protein complex from the nuclear matrix.

Authors:  P C Angeletti; J A Engler
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 4.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

Review 5.  Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals.

Authors:  Subash C Gupta; Ji Hye Kim; Sahdeo Prasad; Bharat B Aggarwal
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

Review 6.  Growth factors, apoptosis, and survival of mammary epithelial cells.

Authors:  E C Rosfjord; R B Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

7.  Mitogen-activated protein kinase (MAPK) pathway mediates the oestrogen-like activities of ginsenoside Rg1 in human breast cancer (MCF-7) cells.

Authors:  Wai-Sum Lau; Wen-Fang Chen; Robbie Yat-Kan Chan; De-An Guo; Man-Sau Wong
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

8.  Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells.

Authors:  Xinguo Jiang; Nicole M Patterson; Yan Ling; Jianwei Xie; William G Helferich; David J Shapiro
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

9.  Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms.

Authors:  Yuanyuan Li; Liang Liu; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

10.  A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.

Authors:  Yoshitaka Nakamura; Shingo Yogosawa; Yasuyuki Izutani; Hirotsuna Watanabe; Eigo Otsuji; Tosiyuki Sakai
Journal:  Mol Cancer       Date:  2009-11-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.